Protalix BioTherapeutics (PLX) Competitors $1.47 -0.07 (-4.55%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$1.55 +0.08 (+5.44%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLX vs. SEPN, SIGA, ORGO, ATYR, KMDA, CGEM, ATAI, MREO, PGEN, and RAPPShould you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include Septerna (SEPN), Siga Technologies (SIGA), Organogenesis (ORGO), aTyr Pharma (ATYR), Kamada (KMDA), Cullinan Therapeutics (CGEM), atai Life Sciences (ATAI), Mereo BioPharma Group (MREO), Precigen (PGEN), and Rapport Therapeutics (RAPP). These companies are all part of the "pharmaceutical products" industry. Protalix BioTherapeutics vs. Its Competitors Septerna Siga Technologies Organogenesis aTyr Pharma Kamada Cullinan Therapeutics atai Life Sciences Mereo BioPharma Group Precigen Rapport Therapeutics Protalix BioTherapeutics (NYSE:PLX) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Do analysts rate PLX or SEPN? Protalix BioTherapeutics currently has a consensus target price of $15.00, indicating a potential upside of 920.41%. Septerna has a consensus target price of $26.75, indicating a potential upside of 146.54%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Protalix BioTherapeutics is more favorable than Septerna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Septerna 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media favor PLX or SEPN? In the previous week, Protalix BioTherapeutics' average media sentiment score of 0.50 beat Septerna's score of 0.00 indicating that Protalix BioTherapeutics is being referred to more favorably in the media. Company Overall Sentiment Protalix BioTherapeutics Positive Septerna Neutral Is PLX or SEPN more profitable? Septerna has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Septerna's return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protalix BioTherapeutics-21.03% -30.89% -11.74% Septerna N/A N/A N/A Do insiders & institutionals hold more shares of PLX or SEPN? 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 6.5% of Protalix BioTherapeutics shares are owned by company insiders. Comparatively, 4.3% of Septerna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, PLX or SEPN? Protalix BioTherapeutics has higher revenue and earnings than Septerna. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtalix BioTherapeutics$59.76M1.96$8.31M$0.0436.75Septerna$1.08M447.66-$71.80MN/AN/A SummaryProtalix BioTherapeutics beats Septerna on 7 of the 12 factors compared between the two stocks. Get Protalix BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLX vs. The Competition Export to ExcelMetricProtalix BioTherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$117.02M$202.48M$5.52B$20.71BDividend YieldN/AN/A5.24%3.72%P/E Ratio-11.31N/A27.2527.80Price / Sales1.96242.79371.3247.05Price / Cash17.8022.4426.2118.22Price / Book3.135.557.944.59Net Income$8.31M-$96.61M$3.17B$982.91M7 Day Performance-0.68%-2.12%1.79%0.65%1 Month Performance-6.96%-2.54%1.27%4.26%1 Year Performance38.68%8.93%33.57%13.93% Protalix BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLXProtalix BioTherapeutics2.757 of 5 stars$1.47-4.5%$15.00+920.4%+40.0%$117.02M$59.76M-11.31200SEPNSepternaN/A$10.57+0.6%$26.75+153.1%N/A$471.00M$1.08M0.00N/ASIGASiga Technologies0.8794 of 5 stars$6.52+0.9%N/A-13.0%$465.79M$138.72M9.7340ORGOOrganogenesis4.0485 of 5 stars$3.66-0.3%$6.00+63.9%+52.9%$464.27M$482.04M-21.53950ATYRaTyr Pharma2.6135 of 5 stars$5.07+0.8%$20.20+298.4%N/A$451.23M$230K-6.2653Gap UpHigh Trading VolumeKMDAKamada3.7683 of 5 stars$7.75+0.5%$14.67+89.2%+36.0%$445.70M$160.95M26.72360Positive NewsCGEMCullinan Therapeutics1.4779 of 5 stars$7.53-3.0%$30.00+298.4%-54.1%$444.35MN/A-2.5930ATAIatai Life Sciences2.9499 of 5 stars$2.19-0.5%$8.67+295.7%+116.5%$438.75M$310K-2.4180Gap UpMREOMereo BioPharma Group1.7823 of 5 stars$2.71+1.9%$7.60+180.4%-19.6%$430.89M$10M-38.7140PGENPrecigen3.6696 of 5 stars$1.42flat$6.00+322.5%+12.0%$419.16M$3.92M-2.54190RAPPRapport Therapeutics1.3077 of 5 stars$11.37-0.5%$32.67+187.3%-49.7%$415.01MN/A-3.30N/A Related Companies and Tools Related Companies Septerna Alternatives Siga Technologies Alternatives Organogenesis Alternatives aTyr Pharma Alternatives Kamada Alternatives Cullinan Therapeutics Alternatives atai Life Sciences Alternatives Mereo BioPharma Group Alternatives Precigen Alternatives Rapport Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PLX) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PLX Stock Alerts